Pharmacy World & Science

, Volume 30, Issue 3, pp 222–226 | Cite as

Change of body weight and lifestyle of persons at risk for diabetes after screening and counselling in pharmacies

  • Andrea Botomino
  • Rudolf Bruppacher
  • Stephan Krähenbühl
  • Kurt E. HersbergerEmail author
Research Article


Objective To investigate the effects of pharmacy based counselling on changes in lifestyle and body weight. Methods Three months after screening a stratified sample of 3,800 randomly chosen overweight persons were addressed with questionnaires. Half a year and 1 year later the assessment was repeated. Standard counselling (SC; non-specific recommendations towards lifestyle), intensive counselling (IC; additional advice to reduce body weight) and counselling for persons at high risk for type 2 diabetes (HRC; recommendation to contact a physician) were compared. Results All counselling groups (SC; n = 557, IC; n = 568, HRC; n = 245) showed significant weight loss three months after screening (0.6–1.9 kg). A further weight reduction was observed at 1 year follow up (1.1–2.4 kg). The HRC group showed a higher percentage of weight loss than the IC or SC group after 3 months (−2.25% vs. −1.20% and −0.67%; P < 0.001) and at 1 year of follow-up (−2.74% vs. −1.54% and −1.29%; P < 0.01). Lifestyle changes in physical activity and/or nutrition were reported by 81.2% in the HRC group, 74.1% in the IC group and 67.0% in the SC group. Conclusion Immediate counselling in community pharmacies after screening for type 2 diabetes can result in significant lifestyle changes and weight loss in overweight individuals.


Body weight Lifestyle change Overweight Pharmaceutical care Type 2 diabetes 



We would like to thank all study participants, Prof. Dr. J. Drewe for support in statistical analysis and S. Mannstadt for her substantial assistance by processing the questionnaires.


This work was funded by the Swiss Federation of Pharmacists, Health Promotion Switzerland and 5 Swiss health insurances (action d).


  1. 1.
    Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403.PubMedCrossRefGoogle Scholar
  3. 3.
    Hersberger KE, Botomino A, Mancini M, Bruppacher R. Sequential screening for diabetes—evaluation of a campaign in Swiss community pharmacies. Pharm World Sci 2006;28(3):171–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot 1997;12(1):38–48.PubMedGoogle Scholar
  5. 5.
    James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000;356(9248):2119–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352(9123):167–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Dzien A, Dzien-Bischinger C, Lechleitner M. Seasonal fluctuation in body mass index. Clin Nutr. 2003;22(4):425–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Visscher TL, Seidell JC. Time trends (1993–1997) and seasonal variation in body mass index and waist circumference in the Netherlands. Int J Obes Relat Metab Disord 2004.Google Scholar
  9. 9.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–421.Google Scholar
  10. 10.
    Ahrens RA, Hower M, Best AM. Effects of weight reduction interventions by community pharmacists. J Am Pharm Assoc (Wash) 2003;43(5):583–9.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Andrea Botomino
    • 1
  • Rudolf Bruppacher
    • 2
  • Stephan Krähenbühl
    • 1
    • 3
  • Kurt E. Hersberger
    • 1
    Email author
  1. 1.Institute of Clinical PharmacyUniversity of BaselBaselSwitzerland
  2. 2.Institute of Social and Preventive MedicineUniversity of BaselBaselSwitzerland
  3. 3.Division of Clinical Pharmacology and ToxicologyUniversity Hospital BaselBaselSwitzerland

Personalised recommendations